Vopratelimab
Vopratelimab Basic information
- Product Name:
- Vopratelimab
- Synonyms:
-
- Vopratelimab
- Research Grade Vopratelimab (DHJ92101)
- Research Grade Vopratelimab
- Vopratelimab (anti-ICOS)
- JTX 2011
- CAS:
- 2039148-04-2
- MW:
- 0
- Mol File:
- Mol File
Vopratelimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Vopratelimab Usage And Synthesis
Uses
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response[1].
in vivo
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice a week, for 2 weeks) promotes tumor regression in the Sa1/N murine syngeneic tumor model[1].
| Animal Model: | Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model[1] |
| Dosage: | 0.25-0.3 mg/kg |
| Administration: | Intraperitoneal injection; twice a week, for 2 weeks |
| Result: | Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model. |
References
[1] Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595. DOI:10.1371/journal.pone.0239595
VopratelimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com